The phase III CheckMate 026 trial tested the efficacy of nivolumab compared to standard first-line chemotherapy (platinum/pemetrexed, platinum/gemcitabine, or carboplatin/paclitaxel) in 423 patients with PD-L1-positive (≥5% of expression by 28–8 clone) advanced NSCLC [31]. Here, CD274 is linked to non-small cell lung carcinoma.